[ { "@id": "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#pubinfo", "@graph": [ { "@id": "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#sig", "http://purl.org/nanopub/x/hasAlgorithm": [ { "@value": "RSA" } ], "http://purl.org/nanopub/x/hasPublicKey": [ { "@value": "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" } ], "http://purl.org/nanopub/x/hasSignature": [ { "@value": "NY+eQcEAzcAHy6mXGLxq0ZWUy+DbAtkjO8jdVG3WPNkhJGjX7+GlbRba4gCdFma1LSMEMY9QzUXlN/vTG0L+VhxA4c9Ik8FityvKkMcfy8hOfjVZGfvYUdj6lnf4OD90Ila45r1EDAshg3p7oaSomsSGVfRhFNhpXAFBbGabUt8=" } ], "http://purl.org/nanopub/x/hasSignatureTarget": [ { "@id": "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0" } ] }, { "@id": "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0", "http://purl.org/dc/terms/created": [ { "@value": "2021-08-23T12:42:57.559+02:00", "@type": "http://www.w3.org/2001/XMLSchema#dateTime" } ], "http://purl.org/dc/terms/creator": [ { "@id": "https://orcid.org/0000-0002-1468-3557" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate": [ { "@id": "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate": [ { "@id": "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate": [ { "@id": "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY" } ] } ] }, { "@id": "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#Head", "@graph": [ { "@id": "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0", "http://www.nanopub.org/nschema#hasAssertion": [ { "@id": "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#assertion" } ], "http://www.nanopub.org/nschema#hasProvenance": [ { "@id": "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#provenance" } ], "http://www.nanopub.org/nschema#hasPublicationInfo": [ { "@id": "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#pubinfo" } ], "@type": [ "http://www.nanopub.org/nschema#Nanopublication" ] } ] }, { "@id": "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#provenance", "@graph": [ { "@id": "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#assertion", "http://www.w3.org/ns/prov#wasAttributedTo": [ { "@id": "https://orcid.org/0000-0002-1468-3557" } ] } ] }, { "@id": "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#assertion", "@graph": [ { "@id": "http://purl.obolibrary.org/obo/DOID_8689", "https://w3id.org/biolink/vocab/category": [ { "@id": "https://w3id.org/biolink/vocab/Disease" } ] }, { "@id": "http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#association", "http://www.w3.org/1999/02/22-rdf-syntax-ns#object": [ { "@id": "http://purl.obolibrary.org/obo/DOID_8689" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate": [ { "@id": "https://w3id.org/biolink/vocab/treats" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject": [ { "@id": "https://identifiers.org/drugbank:DB01156" } ], "@type": [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ], "http://www.w3.org/2000/01/rdf-schema#label": [ { "@value": "\"Seizure disorder. ( 4 5.3 Current or prior diagnosis of bulimia or anorexia nervosa ( 4 5.3 Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, antiepileptic drugs. ( 4 5.3 Monoamine Oxidase Inhibitors (MAOIs): Do not use MAOIs intended to treat psychiatric disorders with bupropion hydrochloride extended-release tablets (XL) or within 14 days of stopping treatment with bupropion hydrochloride extended-release tablets (XL). Do not use bupropion hydrochloride extended-release tablets (XL) within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start bupropion hydrochloride extended-release tablets (XL) in a patient who is being treated with linezolid or intravenous methylene blue. ( 4 7.6 Known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride extended-release tablets (XL) ( 4 5.8 Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with seizure disorder. Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with bupropion hydrochloride Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with seizure disorder. Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with bupropion hydrochloride extended-release tablets (XL) [ see Warnings and Precautions (5.3) Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [ see Warnings and Precautions (5.3) Drug Interactions (7.3) The use of MAOIs (intended to treat psychiatric disorders) concomitantly with bupropion hydrochloride extended-release tablets (XL) or within 14 days of discontinuing treatment with bupropion hydrochloride extended-release tablets (XL) is contraindicated. There is an increased risk of hypertensive reactions when bupropion hydrochloride extended-release tablets (XL) are used concomitantly with MAOIs. The use of bupropion hydrochloride extended-release tablets (XL) within 14 days of discontinuing treatment with an MAOI is also contraindicated. Starting bupropion hydrochloride extended-release tablets (XL) in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated [ see Dosage and Administration (2.9) Warnings and Precautions (5.4) Drug Interactions (7.6) Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride extended-release tablets (XL). Anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported [ see Warnings and Precautions (5.8)\"" } ], "https://w3id.org/biolink/vocab/provided_by": [ { "@id": "https://w3id.org/um/NeuroDKG" } ], "https://w3id.org/biolink/vocab/relation": [ { "@id": "https://schema.org/MedicalContraindication" } ] }, { "@id": "https://identifiers.org/drugbank:DB01156", "https://w3id.org/biolink/vocab/category": [ { "@id": "https://w3id.org/biolink/vocab/Drug" } ] } ] } ]